---
title: HCC70 Orthotopic Model - TD2 Precision Oncology
description: HCC70 is a triple-negative breast cancer cell line, crucial for understanding TNBC biology and developing therapeutic interventions.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/hcc70-1.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# HCC70 Orthotopic Model
**Synonyms:** HCC-70
HCC70 is a cell line derived from human triple-negative breast cancer (TNBC), a subtype characterized by the absence of estrogen receptors, progesterone receptors, and HER2 expression. This cell line provides a critical model for researching TNBC, one of the most aggressive and challenging breast cancer subtypes to treat. HCC70 maintains essential molecular and genetic markers found in TNBC patients, validating its use for in-depth in vitro and in vivo studies. Its behavior, which encompasses tumor growth, metastatic tendencies, and unique resistance mechanisms, mirrors the clinical attributes of TNBC. Researchers worldwide lean on HCC70 to delve into the intricacies of TNBC and to explore and refine innovative treatment options.
## Model Details
**Cancer Type:** Breast Cancer
**Model Name:** HCC70
**Mouse Strain:** Nu/Nu
**Treatment Data Available:** Chemotherapy (Paclitaxel)
## HCC70 Growth curves: Response to Paclitaxel dosed QW
Growth of orthotopic (MFP) HCC70 in Nu/Nu mice (n=6)
### Request Additional Syngeneic Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)